![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: F2R |
Gene summary for F2R |
![]() |
Gene information | Species | Human | Gene symbol | F2R | Gene ID | 2149 |
Gene name | coagulation factor II thrombin receptor | |
Gene Alias | CF2R | |
Cytomap | 5q13.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P25116 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2149 | F2R | LZE4T | Human | Esophagus | ESCC | 6.58e-09 | 9.37e-02 | 0.0811 |
2149 | F2R | LZE24T | Human | Esophagus | ESCC | 8.04e-04 | 7.79e-02 | 0.0596 |
2149 | F2R | P2T-E | Human | Esophagus | ESCC | 4.63e-04 | 5.74e-02 | 0.1177 |
2149 | F2R | P9T-E | Human | Esophagus | ESCC | 5.05e-13 | 3.89e-01 | 0.1131 |
2149 | F2R | P10T-E | Human | Esophagus | ESCC | 4.05e-16 | 2.78e-01 | 0.116 |
2149 | F2R | P11T-E | Human | Esophagus | ESCC | 2.51e-04 | 4.12e-01 | 0.1426 |
2149 | F2R | P12T-E | Human | Esophagus | ESCC | 4.19e-09 | 2.64e-01 | 0.1122 |
2149 | F2R | P15T-E | Human | Esophagus | ESCC | 1.45e-03 | 2.26e-01 | 0.1149 |
2149 | F2R | P19T-E | Human | Esophagus | ESCC | 1.41e-05 | 7.12e-01 | 0.1662 |
2149 | F2R | P20T-E | Human | Esophagus | ESCC | 1.20e-02 | 1.42e-01 | 0.1124 |
2149 | F2R | P21T-E | Human | Esophagus | ESCC | 1.04e-19 | 4.74e-01 | 0.1617 |
2149 | F2R | P22T-E | Human | Esophagus | ESCC | 1.66e-10 | 1.63e-01 | 0.1236 |
2149 | F2R | P26T-E | Human | Esophagus | ESCC | 6.03e-03 | 4.83e-02 | 0.1276 |
2149 | F2R | P28T-E | Human | Esophagus | ESCC | 2.74e-09 | 1.37e-01 | 0.1149 |
2149 | F2R | P30T-E | Human | Esophagus | ESCC | 1.35e-02 | 3.82e-01 | 0.137 |
2149 | F2R | P31T-E | Human | Esophagus | ESCC | 2.35e-19 | 3.27e-01 | 0.1251 |
2149 | F2R | P49T-E | Human | Esophagus | ESCC | 2.52e-11 | 1.10e+00 | 0.1768 |
2149 | F2R | P57T-E | Human | Esophagus | ESCC | 1.92e-03 | 1.43e-01 | 0.0926 |
2149 | F2R | P62T-E | Human | Esophagus | ESCC | 1.33e-03 | 4.05e-02 | 0.1302 |
2149 | F2R | P75T-E | Human | Esophagus | ESCC | 5.92e-05 | 2.28e-02 | 0.1125 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
GO:0044403 | Colorectum | AD | biological process involved in symbiotic interaction | 99/3918 | 290/18723 | 1.02e-07 | 4.93e-06 | 99 |
GO:0007034 | Colorectum | AD | vacuolar transport | 60/3918 | 157/18723 | 4.97e-07 | 1.85e-05 | 60 |
GO:0061008 | Colorectum | AD | hepaticobiliary system development | 55/3918 | 150/18723 | 6.34e-06 | 1.59e-04 | 55 |
GO:0001889 | Colorectum | AD | liver development | 54/3918 | 147/18723 | 7.20e-06 | 1.77e-04 | 54 |
GO:0007041 | Colorectum | AD | lysosomal transport | 42/3918 | 114/18723 | 6.61e-05 | 1.07e-03 | 42 |
GO:0006898 | Colorectum | AD | receptor-mediated endocytosis | 76/3918 | 244/18723 | 1.07e-04 | 1.59e-03 | 76 |
GO:0009791 | Colorectum | AD | post-embryonic development | 29/3918 | 80/18723 | 1.13e-03 | 1.03e-02 | 29 |
GO:0035821 | Colorectum | AD | modulation of process of other organism | 34/3918 | 106/18723 | 4.73e-03 | 3.22e-02 | 34 |
GO:0031100 | Colorectum | AD | animal organ regeneration | 26/3918 | 76/18723 | 4.94e-03 | 3.32e-02 | 26 |
GO:00160321 | Colorectum | SER | viral process | 118/2897 | 415/18723 | 8.36e-12 | 1.65e-09 | 118 |
GO:00487321 | Colorectum | SER | gland development | 112/2897 | 436/18723 | 1.75e-08 | 1.28e-06 | 112 |
GO:00610081 | Colorectum | SER | hepaticobiliary system development | 45/2897 | 150/18723 | 4.98e-06 | 1.85e-04 | 45 |
GO:00018891 | Colorectum | SER | liver development | 44/2897 | 147/18723 | 6.73e-06 | 2.35e-04 | 44 |
GO:00444031 | Colorectum | SER | biological process involved in symbiotic interaction | 72/2897 | 290/18723 | 2.08e-05 | 6.02e-04 | 72 |
GO:00070341 | Colorectum | SER | vacuolar transport | 43/2897 | 157/18723 | 8.92e-05 | 1.93e-03 | 43 |
GO:0048009 | Colorectum | SER | insulin-like growth factor receptor signaling pathway | 14/2897 | 37/18723 | 7.80e-04 | 9.87e-03 | 14 |
GO:00097911 | Colorectum | SER | post-embryonic development | 22/2897 | 80/18723 | 4.12e-03 | 3.36e-02 | 22 |
GO:00160322 | Colorectum | MSS | viral process | 157/3467 | 415/18723 | 7.94e-21 | 6.19e-18 | 157 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513022 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513032 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0513052 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
GZMA | F2R | GZMA_F2R | PARs | Breast | ADJ |
GZMA | F2RL2 | GZMA_F2RL2 | PARs | Breast | ADJ |
GZMA | F2R | GZMA_F2R | PARs | Breast | DCIS |
CTSG | F2RL3 | CTSG_F2RL3 | PARs | Breast | Healthy |
GZMA | F2RL3 | GZMA_F2RL3 | PARs | Breast | Healthy |
GZMA | F2R | GZMA_F2R | PARs | Breast | IDC |
CTSG | F2R | CTSG_F2R | PARs | Cervix | ADJ |
GZMA | F2R | GZMA_F2R | PARs | Cervix | ADJ |
PRSS3 | F2R | PRSS3_F2R | PARs | Cervix | CC |
CTSG | F2R | CTSG_F2R | PARs | Cervix | CC |
GZMA | F2R | GZMA_F2R | PARs | Cervix | CC |
GZMA | F2R | GZMA_F2R | PARs | Cervix | Healthy |
CTSG | F2R | CTSG_F2R | PARs | Cervix | Precancer |
GZMA | F2R | GZMA_F2R | PARs | Cervix | Precancer |
PRSS3 | F2R | PRSS3_F2R | PARs | CRC | AD |
CTSG | F2R | CTSG_F2R | PARs | CRC | AD |
GZMA | F2R | GZMA_F2R | PARs | CRC | AD |
PRSS3 | F2RL3 | PRSS3_F2RL3 | PARs | CRC | AD |
CTSG | F2RL3 | CTSG_F2RL3 | PARs | CRC | AD |
GZMA | F2RL3 | GZMA_F2RL3 | PARs | CRC | AD |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2R | SNV | Missense_Mutation | c.130N>A | p.Leu44Ile | p.L44I | P25116 | protein_coding | tolerated(0.41) | benign(0) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
F2R | SNV | Missense_Mutation | c.1258N>C | p.Tyr420His | p.Y420H | P25116 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3511-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
F2R | SNV | Missense_Mutation | c.1007A>T | p.His336Leu | p.H336L | P25116 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
F2R | SNV | Missense_Mutation | rs375693604 | c.493G>A | p.Gly165Ser | p.G165S | P25116 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2R | SNV | Missense_Mutation | c.973T>A | p.Cys325Ser | p.C325S | P25116 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A02W-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
F2R | SNV | Missense_Mutation | rs752231723 | c.527N>A | p.Arg176His | p.R176H | P25116 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
F2R | SNV | Missense_Mutation | c.154T>C | p.Tyr52His | p.Y52H | P25116 | protein_coding | tolerated(0.41) | possibly_damaging(0.459) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
F2R | SNV | Missense_Mutation | novel | c.278N>T | p.Ser93Phe | p.S93F | P25116 | protein_coding | deleterious(0.03) | benign(0.177) | TCGA-AG-3726-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F2R | SNV | Missense_Mutation | novel | c.872T>G | p.Val291Gly | p.V291G | P25116 | protein_coding | deleterious(0) | possibly_damaging(0.623) | TCGA-AG-A02G-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | PD |
F2R | SNV | Missense_Mutation | rs746379887 | c.562N>A | p.Ala188Thr | p.A188T | P25116 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | inhibitor | CHEMBL2013119 | RIGOSERTIB SODIUM | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | TYROSINE KINASE INHIBITOR | 15383630 | ||
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | MORPHINE | MORPHINE | 12373743 | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | ETHANOL | ALCOHOL | 16930224 | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | 405560412 | ||
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | CHEMBL2103856 | ATOPAXAR | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | CHEMBL2107386 | VORAPAXAR SULFATE | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | WORTMANNIN | WORTMANNIN | 10318860,7559410,8955143 | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | 178100871 | VORAPAXAR | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | agonist | 178100667 |
Page: 1 2 3 4 |